CD274 and non-small cell lung carcinoma: Among NSCLC patients receiving treatment with pembrolizumab, those with a PD-L1 TPS ≥ 50% had an objective response rate (ORR) of 45.2%, whereas the ORR was 16.5% for those with a TPS between 1% and 49% and only 10.7% for those with a TPS < 1% (10).